... May 20
Latest Pharma News Update... Aug 23
Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin ... Sep 20
-Advertisements-